Electrophysiology & Arrhythmia

Breast cancer patients under 60 years old are nearly twice as likely as their healthy counterparts to develop both short- and long-term atrial fibrillation (AF), researchers reported Jan. 29 in Heart Rhythm.

Non-vitamin K oral anticoagulants (NOACs) including dabigatran, rivaroxaban, apixaban and edoxaban have replaced warfarin as the preferred treatment for reducing stroke risk in patients with atrial fibrillation, according to updated guidelines issued Jan. 28.

Royal Philips and the American Heart Association are collaborating for a new program devoted to increasing survival rates in patients who experience sudden cardiac arrest (SCA), the organizations announced Jan. 23.

Another smartwatch has received FDA clearance for an electrocardiogram (ECG) feature. But this one—the Study Watch from Alphabet’s health division, Verily—is a “prescription-only device” rather than a product marketed to all consumers.

Leadless pacemakers are a viable alternative to conventional pacemakers in patients with a history of device infection and lead extraction, researchers reported in the January edition of Heart Rhythm.

Abbott on Jan. 21 announced the FDA approval of one of its atrial fibrillation (AFib) ablation catheters, the TactiCath Contact Force Ablation Catheter.

The majority of patients who present to the emergency department (ED) after fainting likely don’t need to be monitored for more than two hours to rule out any dangerous underlying arrhythmias, Canadian researchers have found.

A prospective, single-center study from Denmark suggests nearly half of patients develop a new conduction abnormality after transcatheter aortic valve replacement (TAVR), impacting their short-term and long-term prognosis.

Young victims of sudden cardiac arrest (SCA) and death are more likely to have a history of cardiovascular disease and some relationship with drugs or psychiatric illness, according to research published Jan. 19 in the Journal of the American Heart Association.

Women implanted with cardiac implantable electronic devices (CIEDs) like pacemakers, implantable cardioverter defibrillators and cardiac resynchronization therapy technologies are more likely to experience acute CIED complications than men who undergo the same procedures, according to work published Jan. 16 in the Journal of the American Heart Association.

Medtronic announced on Jan. 15 the launch of a mobile app that connects four of the company’s pacemakers to patients’ smartphones and tablets, removing the need for bedside monitors or other remote monitoring equipment.

Patients with atrial fibrillation can safely continue oral anticoagulation (OAC) while undergoing transcatheter aortic valve replacement (TAVR), suggests a retrospective study published Jan. 7 in the American Journal of Cardiology.